The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review

References

• VidailhetM. Movement disorders in 2010: Parkinson disease-symptoms and treatments. Nat Rev Neurol. 2011;7:70–72. doi:10.1038/nrneurol.2010.21621297648
   PubMed Web of Science ®Google Scholar
• LeWittPA, FahnS. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016;86:S3–12. doi:10.1212/WNL.000000000000250927044648
   PubMed Web of Science ®Google Scholar
• CoelhoM, FerreiraJJ. Late-stage Parkinson disease. Nat Rev Neurol. 2012;8:435–442. doi:10.1038/nrneurol.2012.12622777251
   PubMed Web of Science ®Google Scholar
• AntoniniA, ChaudhuriKR, Martinez-MartinP, OdinP. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs. 2010;24:119–129. doi:10.2165/11310940-000000000-0000020088619
   PubMed Web of Science ®Google Scholar
• MurataM, MiharaM, HasegawaK, et al. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease. Ther Adv Neurol Disord. 2018;11:1756286418759315. doi:10.1177/175628641875931529511383
   PubMed Web of Science ®Google Scholar
• UddM, LyytinenJ, Eerola-RautioJ, et al. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease. Brain Behav. 2017;7:e00737. doi:10.1002/brb3.2017.7.issue-728729942
   PubMed Web of Science ®Google Scholar
• NyholmD. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother. 2006;6:1403–1411. doi:10.1586/14737175.6.10.140317078781
   PubMedGoogle Scholar
• EpsteinM, JohnsonDA, HawesR, et al. Long-term PEG-J tube safety in patients with advanced Parkinson’s disease. Clin Transl Gastroenterol. 2016;7:e159. doi:10.1038/ctg.2016.1927030949
   PubMed Web of Science ®Google Scholar
• MacleodMR, O’CollinsT, HowellsDW, DonnanGA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004;35:1203–1208. doi:10.1161/01.STR.0000125719.25853.2015060322
   PubMed Web of Science ®Google Scholar
• VesterinenHM, SenaES, EganKJ, et al. Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods. 2014;221:92–102. doi:10.1016/j.jneumeth.2013.09.01024099992
   PubMed Web of Science ®Google Scholar
• IoannidisJP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14:951–957. doi:10.1111/j.1365-2753.2008.00986.x19018930
   PubMed Web of Science ®Google Scholar
• NyholmD, AskmarkH, Gomes-TrolinC, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26:156–163. doi:10.1097/00002826-200305000-0001012782919
   PubMed Web of Science ®Google Scholar
• NyholmD, Nilsson RemahlAI, DizdarN, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216–223. doi:10.1212/01.WNL.0000149637.70961.4C15668416
   PubMed Web of Science ®Google Scholar
• OlanowCW, KieburtzK, OdinP, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–149. doi:10.1016/S1474-4422(13)70293-X24361112
   PubMed Web of Science ®Google Scholar
• OthmanAA, DuttaS. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78:94–105. doi:10.1111/bcp.2014.78.issue-124433449
   PubMed Web of Science ®Google Scholar
• AntoniniA, FungVS, BoydJT, et al. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov Disord. 2016;31:530–537. doi:10.1002/mds.2652826817533
   PubMed Web of Science ®Google Scholar
• Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738–750. doi:10.1002/(ISSN)1531-825712815652
   PubMed Web of Science ®Google Scholar
• PetoV, JenkinsonC, FitzpatrickR, GreenhallR. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4:241–248. doi:10.1007/BF022608637613534
   PubMed Web of Science ®Google Scholar
• EspayAJ, MorganteF, MerolaA, et al. Levodopa-induced dyskinesia in Parkinson disease: current and Evolving Concepts. Ann Neurol. 2018;84:797–811. doi:10.1002/ana.2536430357892
   PubMed Web of Science ®Google Scholar
• FahnS, OakesD, ShoulsonI, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508.15590952
   PubMed Web of Science ®Google Scholar
• RamakerC, MarinusJ, StiggelboutAM, Van HiltenBJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17:867–876. doi:10.1002/(ISSN)1531-825712360535
   PubMed Web of Science ®Google Scholar
• GoetzCG, FahnS, Martinez-MartinP, et al. Movement disorder society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22:41–47. doi:10.1002/(ISSN)1531-825717115387
   PubMed Web of Science ®Google Scholar
• GoetzCG, TilleyBC, ShaftmanSR, et al. Movement disorder society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–2170. doi:10.1002/mds.v23:1519025984
   PubMed Web of Science ®Google Scholar
• FernandezHH, StandaertDG, HauserRA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30:500–509. doi:10.1002/mds.2612325545465
   PubMed Web of Science ®Google Scholar